




JFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 15, 2004.


Signature

Applicant : Jorge R. Barrio, et al.
Application No. : 10/680,818
Filed : October 7, 2003
Title : COMPOSITIONS FOR LABELING BETA-AMYLOID PLAQUES AND
NEUROFIBRILLARY TANGLES
Grp./Div. : 1641
Examiner : Not Yet Assigned
Docket No. : 50319/JDC/R268

**INFORMATION DISCLOSURE STATEMENT
FOR A CONTINUING NON-CPA APPLICATION**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Post Office Box 7068
Pasadena, CA 91109-7068
June 15, 2004

Commissioner:

In compliance with the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, enclosed is
FORM PTO/SB/08A/B.


The references listed thereon are not enclosed because they were of record in the parent
application, Application No. 09/891,883, filed June 26, 2001.

It is respectfully requested that these references be considered in the examination of this
application, and identified in the list of references cited on the patent issuing on this application.


Respectfully submitted,

CHRISTIE, PARKER & HALE, LLP

By


John D. Carpenter
Reg. No. 34,133
626/795-9900

JDC/srh
Enclosure(s)
568053_1.DOC



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Attorney Docket Number	50319/JDC/R268
Application Number	10/680,818
Filing Date	October 7, 2003
Applicant(s)	Jorge R. Barrio, et al.
Group Art Unit	1641
Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS


EXAMINER INITIALS	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (If Known)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE
		5,227,308	07-13-1993	Jameson et al.
		5,614,502	03-25-1997	Flotte et al.

OTHER DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Jacobson, A., "1,1-Dicyano-2-[6-(dimethylamino)naphthalen-2-yl]propene (DDNP): A Solvent Polarity and Viscosity Sensitive Fluorophore for Fluorescence Microscopy", J. Am. Chem. Soc., 1996, Vol. 118, No. 2, pp. 5572-5579.
		N. Alizadeh-Pasdar and E. C. Y. Li-Chan, "Application of PRODAN Fluorescent Probe to Measure Surface Hydrophobicity of Proteins Interacting with K-carrageenan" The IFT 1999 Annual Meeting, one page.
		Klunk, W., et al., "Development of Small Molecule Probes for the Beta-Amyloid Protein of Alzheimer's Disease", Neurobiology of Aging, Vol. 15, No. 6, pp. 691-698, 1994.
		Klunk, W., et al., "Chrysamine-G Binding to Alzheimer and Control Brain: Autopsy Study of a New Amyloid Probe", Neurobiology of Aging, Vol. 16, No. 4, pp. 541-548, 1993.
		Dezutter, et al., "Preparation of ^{99m} Tc-N ₂ S ₂ Conjugates of Chrysamine G, Potential Probes for the Beta-Amyloid Protein of Alzheimer's Disease," Journal of Labelled Compounds and Radiopharmaceuticals J. Labelled Cpd. Radiopharm. 42, (1999) 309-324
		Griffiths, P.D., et al., "Receptor Changes in the Neocortex of Post-Mortem Tissue in Parkinson's Disease and Alzheimer's Disease", Dementia, Vol. 3, (1992) pp. 239-246
		Han, et al., "Technetium Complexes for the Quantitation of Brain Amyloid," J. Am. Chem. Soc. 1996, 118, 4506-4507
		Huang, et al., "Neuroreceptor Assay with Positron Emission Tomography: Equilibrium Versus Dynamic Approaches," Journal of Cerebral Blood Flow and Metabolism (1986) 6:515-521
		Imamura, et al., "Regional Cerebral Glucose Metabolism in Dementia with Lewy Bodies and Alzheimer's Disease: a Comparative Study Using Positron Emission Tomography," Neuroscience Letters 235 (1997) 49-52

EXAMINER SIGNATURE		DATE CONSIDERED	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. ³Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.



INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Attorney Docket Number	50319/JDC/R268
Application Number	10/680,818
Filing Date	October 7, 2003
Applicant(s)	Jorge R. Barrio, et al.
Group Art Unit	1641
Examiner Name	Not Yet Assigned

OTHER DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Klunk, et al., "Development of Small Molecule Probes for the Beta-Amyloid Protein of Alzheimer's Disease," <i>Neurobiology of Aging</i> , Vol. 15, No. 6, (1994) pp. 691-698
		Majocha, et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <i>The Journal of Nuclear Medicine</i> , Vol. 33, No. 12, December 1992, pp. 2184-2189
		Merlini, et al., "Interaction of the Anthracycline 4'-iodo-4'-deoxydoxorubicin with Amyloid Fibrils: Inhibition of Amyloidogenesis," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, March 1995, pp. 2959-2963
		Mielke, et al., "Regional Cerebral Glucose Metabolism and Postmortem Pathology in Alzheimer's Disease," <i>Acta Neuropathol</i> (1996) 91:174-179
		Morys, et al., "The Second Layer Neurones of the Entorhinal Cortex and the Perforant Path in Physiological Ageing and Alzheimer's Disease," <i>Acta Neurobiol. Exp.</i> (1994) 54:47-53
		Naiki, et al., "Fluorometric Determination of Amyloid Fibrils <i>in Vitro</i> Using the Fluorescent Dye, Thioflavine T," <i>Analytical Biochemistry</i> 177, (1989) 244-249
		Price, et al., "Tangles and Plaques in Nondemented Aging and "Preclinical" Alzheimer's Disease," <i>Ann Neurol</i> (1999) 45:358-368
		Saito, et al., "Vector-mediated Delivery of ¹²⁵ I-Labeled β -amyloid Peptide A β ¹⁻⁴⁰ Through the Blood-brain Barrier and Binding to Alzheimer Disease Amyloid of the A β ¹⁻⁴⁰ / Vector Complex," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, October 1995, pp. 10227-10231
		Salmon, et al., "Differential Diagnosis of (Alzheimer's) Disease with PET," <i>The Journal of Nuclear Medicine</i> , Vol. 35, No. 3, March (1994) pp. 391-398
		Tubis, et al., "The Preparation and Use of Radioiodinated Congo Red in Detecting Amyloidosis," <i>Journal of the American Pharmaceutical Association</i> , Vol. 49, No. 7, July 1960, pp. 422-425

568224_1.DOC

EXAMINER SIGNATURE	DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. ³Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.</p>	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE